fda semaglutide compounding is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Trimi GLP-1 Review 2026: What

While trezepatide shows a slight edge in weight loss and potential cardiovascular benefits, the choice ultimately depends on individual patient needs

Optimizing your individual timeline While average timelines provide useful guidance, optimizing your personal response requires attention to factors you can control and awareness of those you cannot

Free radicals are unstable molecules that can damage cells, leading to inflammation and oxidative stress

Many people with problematic drinking patterns never seek formal treatment due to stigma, lack of awareness, or ambivalence about changing their drinking

However, these animal findings are concerning enough that drug manufacturers and regulatory agencies have recommended caution until we have better human data

Novo Nordisk said in an email to CNN that it has been in ongoing dialogue with the FDA regarding the manufacturing and supply of Wegovy and Ozempic, and the company has remained confident in its supply since the shortage ended